FDA approves once-monthly Abilify Maintena (aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia

-- Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation -- Relapse prevention is an important consideration in the treatment of patients with schizophrenia; Abilify Maintena(TM) met the phase III clinical trial primary endpoint of significantly delaying time to relapse -- Abilify Maintena will be the first commercialized product from the global alliance be
Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news